OptiNose (OPTN) Stock

DelistedNasdaq: OPTNOptiNose, Inc., a specialty pharmaceutical company, focuses on the development and commercialization of products for patients treated by ear, nose, throat, and allergy specialists.

9.71
Final close · May 19, 2025

OPTN is no longer traded. OptiNose was delisted from the Nasdaq in May 2025.

Prices on this page are historical; the last trade was May 19, 2025 at $9.71.

OptiNose stock price history

Split-adjusted closes, 2017–2025

OPTN final trading statistics

Final close
$9.71
Final trading day
May 19, 2025
Market cap at delisting
$98.34M
Shares outstanding
10.13M
Final 52-week range
$0.32 – $9.75
Avg. volume (final 3 mo.)
94,673
All-time high (split-adj.)
$446.40 · Jul 2018
All-time low (split-adj.)
$5.00 · Jan 2025
Return since IPO
-96.6%
Beta
-0.89
Book value / share
-$6.06
Price / book
-1.60
Final 52 wk
0.329.75

OptiNose earnings per share

Earnings per share

OptiNose revenue & net income

RevenueNet income

OptiNose annual financials

Fiscal yearRevenueNet incomeEPS
FY2024$78.23M-$21.5M-$0.20
FY2023$70.99M-$35.5M-$0.32
FY2022$76.28M-$76.4M-$0.89
FY2021$74.65M-$81.7M-$1.48
FY2020$49.12M-$98.3M-$2.08

Last five fiscal years reported before the delisting; fiscal year ending December. EPS is adjusted (non-GAAP) EPS as reported. Source: company filings via EODHD.

About OptiNose

OptiNose, Inc., a specialty pharmaceutical company, focuses on the development and commercialization of products for patients treated by ear, nose, throat, and allergy specialists. It offers XHANCE, a therapeutic product utilizing its proprietary exhalation delivery system (EDS) that delivers a topically acting corticosteroid for the treatment of chronic rhinosinusitis with nasal polyps, as well as is in Phase III clinical trial for treatment of chronic sinusitis; and Onzetra Xsail, a powder EDS device. The company was founded in 2000 and is headquartered in Yardley, Pennsylvania. As of May 21, 2025, OptiNose, Inc. operates as a subsidiary of Paratek Pharmaceuticals, Inc.

OptiNose stock FAQ

What happened to OptiNose stock?

OptiNose stock was delisted from the Nasdaq. Its final close was $9.71 on May 19, 2025.

Is OPTN stock still trading?

No. OPTN was delisted from the Nasdaq in May 2025 and no longer trades on a U.S. exchange.

What was the last price of OPTN stock?

OPTN closed at $9.71 on its final trading day, May 19, 2025, for a market value of about $98.34M.

What were OptiNose's revenue and earnings in its last full fiscal year?

OptiNose reported revenue of $78.23M and net income of -$21.5M in fiscal 2024, its last full year as a public company.

When did OptiNose go public?

OptiNose stock began trading on October 13, 2017.

Drug Manufacturers - Specialty & Generic stocks to research

All Healthcare stocks →